BRCA1, TXR1, and TSP1 mRNA Expression and Lung Cancer Treatment Outcomes
Author Information
Author(s): Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J
Primary Institution: University of Crete
Hypothesis
The study investigates the predictive significance of BRCA1, TXR1, and TSP1 mRNA expression in non-small-cell lung cancer patients treated with docetaxel-based chemotherapy.
Conclusion
The study indicates that TXR1/TSP1 and BRCA1 expression could be used to predict resistance to taxanes in the treatment of non-small-cell lung cancer.
Supporting Evidence
- Low TXR1 mRNA levels were associated with higher response rates and longer survival.
- High TSP1 expression correlated with better treatment outcomes.
- High BRCA1 expression was linked to increased progression-free survival.
Takeaway
This study looked at how certain genes in lung cancer patients can help doctors understand how well chemotherapy will work for them.
Methodology
The study analyzed mRNA expression from microdissected primary tumors using RT-qPCR.
Limitations
The study is retrospective and lacks a non-taxane-treated control group.
Participant Demographics
{"gender":{"male":106,"female":25},"age":{"median":60,"range":"37–78"},"performance_status":{"0":67,"1":52,"2":12},"stage":{"IIIB":35,"IV":96},"histology":{"adenocarcinoma":68,"squamous":56,"other":7}}
Statistical Information
P-Value
{"TXR1":{"low":{"RR":0.018,"PFS":0.029,"OS":0.003},"high":null},"TSP1":{"low":{"PFS":"<0.001","OS":"<0.001"},"high":{"RR":0.035}},"BRCA1":{"low":{"PFS":0.021,"RR":0.028,"OS":0.4},"high":{"PFS":0.001}}}
Confidence Interval
{"PFS":"95% CI 2.7–5.7","OS":"95% CI 9.7–14.6"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website